The Russian Sputnik V coronavirus vaccine is likely to offer up to 2 years of immunity against Covid-19, compared to 4-5 months of immunity that could be obtained by using the Covid vaccine developed by Pfizer and BioNTech. The Gamaleya Research Center, which is developing the Sputnik V vaccine, made the statement on Monday.
A report from Wion quoted Alexander Gintsburg, head of the Gamaleya Research Institute in Russia, as saying: “Regarding our vaccine and the platform on which it was created, the Ebola vaccine, there is experimental evidence that the use of this platform, using training methods similar, provides protection for at least two years, maybe more. “
Further elaborating on the immunity expected to be obtained through the use of the Pfizer vaccine, Alexander Gintsburg said: “It is difficult to say how long the Pfizer vaccine will give immunity, but based on the general findings of these vaccines, we must believe that the protection period will not be older than four to five months, although this requires experimental data. “
Earlier this year, Russia became the first country in the world to register a Covid-19 vaccine – Sputnik-V – named after Russia’s first satellite. A mass vaccination program was launched last week, with developers saying the vaccine is 95% effective based on the results of interim studies.
A press release from researchers at the Gamaleya Institute announced that the experimental coronavirus Sputnik-V vaccine shows 91.4% efficacy based on analysis of data from the final checkpoint of clinical trials.
“The effectiveness of the Sputnik V vaccine is 91.4%, based on the analysis of the final control point of the data obtained 21 days after the administration of the first dose,” the statement reads.
According to the official website of Sputnik-V, “the advance to the third and last statistically significant representative checkpoint allowed the final proof of vaccine efficacy of over 90%”.
RDIF CEO Kirill Dmitriev: “Today the Gamaleya Institute and the Russian Direct Investment Fund will announce the results of their effectiveness #SputnikV vaccine at the final checkpoint of clinical trials “- @rdif_press.
– Sputnik V (@sputnikvaccine) December 14, 2020
However, the center’s deputy director of science, Denis Logunov, said the institute expects the vaccine to be more effective.
However, despite the start of Russia’s vaccination campaign, Sputnik V has not yet completed the third and final phase of studies involving about 40,000 volunteers.
Meanwhile, the coronavirus vaccine developed by Pfizer demonstrated 95% efficacy in the late-stage study, the company said earlier.
In a major evolution, the US is now the sixth country to approve the two-dose regimen, after the United Kingdom, Bahrain, Canada, Saudi Arabia and Mexico.
After the United Kingdom, the United States and Canada became the other two nations in the world to start vaccinating against Covid-19 with the Pfizer-BioNtech vaccine dose. Both the United States and Canada have begun administering the dose of Pfizer coronavirus vaccine to health care workers and the elderly.
(With entries from AFP)